Compare CACI & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CACI | NUVL |
|---|---|---|
| Founded | 1962 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6B | 9.8B |
| IPO Year | 2007 | 2021 |
| Metric | CACI | NUVL |
|---|---|---|
| Price | $525.60 | $123.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 16 |
| Target Price | ★ $689.50 | $134.75 |
| AVG Volume (30 Days) | 252.7K | ★ 2.7M |
| Earning Date | 04-22-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.00 | N/A |
| EPS | ★ 17.11 | N/A |
| Revenue | ★ $4,467,860,000.00 | N/A |
| Revenue This Year | $12.42 | N/A |
| Revenue Next Year | $10.00 | $1,239.49 |
| P/E Ratio | $30.46 | ★ N/A |
| Revenue Growth | ★ 2.60 | N/A |
| 52 Week Low | $439.67 | $71.14 |
| 52 Week High | $683.50 | $123.62 |
| Indicator | CACI | NUVL |
|---|---|---|
| Relative Strength Index (RSI) | 55.95 | 66.62 |
| Support Level | $490.31 | $97.71 |
| Resistance Level | $539.13 | N/A |
| Average True Range (ATR) | 18.64 | 4.24 |
| MACD | 2.60 | 2.74 |
| Stochastic Oscillator | 69.23 | 99.49 |
CACI International Inc is an information solutions and services provider, offering information solutions and services to its customers. The company's primary customers are agencies and departments of the U.S. government, which account for the vast majority of the firm's revenue. It provides information solutions and services supporting national security missions and government modernization for intelligence, defense, and federal civilian customers. Some of the services provided by the company are functional software development, data, and business analysis, IT operations support, naval architecture, and life cycle support intelligence among others. The company's operating segments are; Domestic operations and International operations. It derives key revenue from the Domestic segment.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.